Portfolio

Meneldor invests in high-impact, science-driven innovations that address significant unmet medical needs and can be accelerated through smart translational strategies.

All our (bio)pharmaceutical platforms and drug candidates have:

a compelling mechanistic rationale
robust preclinical validation
a clear and value-creating path to clinical, regulatory and commercial milestones
Teams that can execute under uncertainty

We invest as much in people as in science. Strong biology only creates value when led by teams with sound judgment, development experience and the discipline to make hard prioritization choices. Team quality is therefore a core investment criterion and a key lever in our risk management and value creation approach.

Investments

Mithrilium Therapeutics

Mithrilium Therapeutics is advancing MT-101, a broad-spectrum, host-directed therapeutic for viral pneumonia

TIBEAY BioSciences

First-in-class therapy for acute moderate and severe traumatic brain injury

Stealth 1

Women’s health has been historically underfunded and underserved, despite clear unmet need and strong scientific opportunity.

HEMISPHERIAN

Redefining treatment for aggressive cancers through TET2-targeted therapeutics

TAGWORKS PHARMACEUTICALS

Tagworks Pharmaceuticals is a clinical-stage precision oncology company using its proprietary Click-to-Release linker platform to develop a new standard of care for patients suffering from solid tumors.

LIGHTOX

Precision light-activated therapeutics and translational imaging tools

APTAMER GROUP

Transforming discovery with next-generation aptamer technology

PHILIKOS

Philikos, a privately held biotechnology company based in the Netherlands, is developing antibody-based therapies for the treatment of severe immune disorders.

This website is intended exclusively for professional and qualified investors. It is not directed at retail investors or consumers.